US Pharma MarketingAusperBio raises $120m to progress hepatitis B therapies
AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B. AusperBio’s total capital raised since 2024 has reached $360m. The funds will advance AHB-137, an antisense oligonucleotide therapy for chronic hepatitis B, towards Phase III and commercial readiness. Credit: Jo Panuwat D / Shutterstock.com. AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B (CHB). NPVM: Altimmune Inc's HepTcell Go deeper with GlobalData The gold standard of business intelligence. Combine…
AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.
Source: Pharmaceutical Technology